Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.

Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K, Anant S.

J Hematol Oncol. 2017 Jan 7;10(1):10. doi: 10.1186/s13045-016-0373-z. Review.

2.

Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.

Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, Esfandiari N, Ma M, Baracos VE.

J Cachexia Sarcopenia Muscle. 2016 May;7(2):126-35. doi: 10.1002/jcsm.12039. Epub 2015 Jun 9.

3.

Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests.

Guéchot J, Boursier J, de Ledinghen V, Poynard T, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group and/or AFEF.

Clin Chem Lab Med. 2015 Jul;53(8):1135-7. doi: 10.1515/cclm-2015-0241. No abstract available.

4.

Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.

Angulo P, Machado MV, Diehl AM.

Semin Liver Dis. 2015 May;35(2):132-45. doi: 10.1055/s-0035-1550065. Epub 2015 May 14. Review.

PMID:
25974899
5.

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F.

Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.

6.

Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.

Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P.

Dig Liver Dis. 2015 Mar;47(3):181-90. doi: 10.1016/j.dld.2014.09.020. Epub 2014 Nov 18. Review.

7.

The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N.

Dig Dis Sci. 2015 May;60(5):1440-7. doi: 10.1007/s10620-014-3494-7. Epub 2014 Dec 25.

PMID:
25540086
8.

An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.

Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group; AFEF.

J Hepatol. 2015 Apr;62(4):807-15. doi: 10.1016/j.jhep.2014.10.042. Epub 2014 Nov 5.

PMID:
25450206
9.

Noninvasive prediction of hepatic steatosis.

Cumberledge J, Angulo P.

Am J Gastroenterol. 2014 Sep;109(9):1415-6. doi: 10.1038/ajg.2014.265.

PMID:
25196872
10.

Hepatic steatosis and steatohepatitis: Are they really two distinct entities?

Fielding CM, Angulo P.

Curr Hepatol Rep. 2014 Jun 1;13(2):151-158.

11.

Right upper-quadrant pain in a patient with drug abuse, secondary syphilis and occult hepatitis B virus.

Fielding CM, Angulo P.

Med Princ Pract. 2014;23(5):471-4. doi: 10.1159/000360401. Epub 2014 Mar 18.

12.

INTERVENCIONES.

Prado S, López-Ibor, Angulo P, Martínez-Fornés, Fernández B, Aragón V, Campos.

An R Acad Nac Med (Madr). 2014;131(2):492-6. Spanish. No abstract available.

PMID:
27400569
13.

INTERVENCIONES.

Vela M, Angulo P, de Peralta T, Manuel C, Rodríguez R.

An R Acad Nac Med (Madr). 2014;131(2):469-76. Spanish. No abstract available.

PMID:
27400567
14.

Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease.

Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, Liaquat H, Mezzabotta L, Lee E, Bugianesi E.

Clin Gastroenterol Hepatol. 2014 Jul;12(7):1163-1169.e1. doi: 10.1016/j.cgh.2013.11.035. Epub 2013 Dec 14.

15.

Noninvasive evaluation of NAFLD.

Castera L, Vilgrain V, Angulo P.

Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):666-75. doi: 10.1038/nrgastro.2013.175. Epub 2013 Sep 24. Review.

PMID:
24061203
16.

Strengthening the bones in primary biliary cirrhosis.

Angulo P.

Hepatology. 2013 Dec;58(6):1871-3. doi: 10.1002/hep.26696. Epub 2013 Oct 17. No abstract available.

17.

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J.

Gastroenterology. 2013 Oct;145(4):782-9.e4. doi: 10.1053/j.gastro.2013.06.057. Epub 2013 Jul 13.

18.

PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.

Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.

J Surg Res. 2013 Nov;185(1):225-30. doi: 10.1016/j.jss.2013.05.016. Epub 2013 May 25.

19.

Risk factors for venous thromboembolism in patients with chronic liver disease.

Walsh KA, Lewis DA, Clifford TM, Hundley JC, Gokun Y, Angulo P, Davis GA.

Ann Pharmacother. 2013 Mar;47(3):333-9. doi: 10.1345/aph.1R496. Epub 2013 Mar 12.

PMID:
23482730
20.

Can NASH be diagnosed, graded, and staged noninvasively?

Grandison GA, Angulo P.

Clin Liver Dis. 2012 Aug;16(3):567-85. doi: 10.1016/j.cld.2012.05.001. Epub 2012 Jun 26. Review.

21.

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.

Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.

Anticancer Res. 2012 Jul;32(7):2531-6.

PMID:
22753710
22.

Cryoglobulins in nonalcoholic Fatty-liver disease: what is the association?

Bryson BC, Angulo P.

Gastroenterol Hepatol (N Y). 2012 Apr;8(4):281-3. No abstract available.

23.

Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease.

Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P.

Clin Gastroenterol Hepatol. 2012 Sep;10(9):1028-33.e2. doi: 10.1016/j.cgh.2012.05.008. Epub 2012 May 18.

24.

The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease.

Charatcharoenwitthaya P, Lindor KD, Angulo P.

Dig Dis Sci. 2012 Jul;57(7):1925-31. doi: 10.1007/s10620-012-2098-3. Epub 2012 Feb 29.

PMID:
22373863
25.

The Framingham risk score and heart disease in nonalcoholic fatty liver disease.

Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P.

Liver Int. 2012 Jul;32(6):945-50. doi: 10.1111/j.1478-3231.2011.02753.x. Epub 2012 Feb 2.

26.

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.

J Surg Res. 2012 Aug;176(2):542-8. doi: 10.1016/j.jss.2011.10.045. Epub 2011 Nov 21.

PMID:
22261591
27.

Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply.

Gedaly R, Daily MF, Davenport DL, McHugh PP, Angulo P, Hundley JC.

Arch Surg. 2012 Jan 16;147(1):99. doi: 10.1001/archsurg.147.1.99. No abstract available.

PMID:
27284786
28.

Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.

Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, Hundley JC.

Arch Surg. 2011 Aug;146(8):953-8. doi: 10.1001/archsurg.2011.186.

PMID:
21844436
29.

Clinical trials: Trial design in NASH--realities and challenges.

Angulo P.

Nat Rev Gastroenterol Hepatol. 2011 Aug 5;8(8):424-5. doi: 10.1038/nrgastro.2011.125. No abstract available.

PMID:
21818144
30.

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J.

Hepatology. 2011 Oct;54(4):1208-16. doi: 10.1002/hep.24491. Epub 2011 Aug 9.

31.

Nonalcoholic fatty liver disease: what are the odds your patient will get a transplant?

Leverage SC, Angulo P.

Clin Gastroenterol Hepatol. 2011 Aug;9(8):631-2. doi: 10.1016/j.cgh.2011.05.018. Epub 2011 May 30. No abstract available.

PMID:
21683162
32.

Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.

Angulo P.

Hepatology. 2011 Jun;53(6):1792-4. doi: 10.1002/hep.24403. No abstract available.

PMID:
21557278
33.

Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease.

Carter-Kent C, Brunt EM, Yerian LM, Alkhouri N, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE.

J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):190-7. doi: 10.1097/MPG.0b013e3181fb47d3.

PMID:
21240012
34.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

35.

A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis.

Adams LA, Angulo P, Petz J, Keach J, Lindor KD.

Hepatol Int. 2010 Jul 28;4(3):628-33. doi: 10.1007/s12072-010-9195-1.

36.

Bone disease in patients with primary sclerosing cholangitis.

Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, Koch A.

Gastroenterology. 2011 Jan;140(1):180-8. doi: 10.1053/j.gastro.2010.10.014. Epub 2010 Oct 16.

37.

Varices in early histological stage primary biliary cirrhosis.

Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD.

J Clin Gastroenterol. 2011 Aug;45(7):e66-71. doi: 10.1097/MCG.0b013e3181f18c4e.

PMID:
20856137
38.

Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P.

Am J Gastroenterol. 2010 Jul;105(7):1567-73. doi: 10.1038/ajg.2010.18. Epub 2010 Feb 9.

39.

Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?

Angulo P.

Hepatology. 2010 Feb;51(2):373-5. doi: 10.1002/hep.23521. No abstract available. Erratum in: Hepatology. 2010 May;51(5):1868.

40.

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.

Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD.

Hepatology. 2009 Dec;50(6):1818-26. doi: 10.1002/hep.23239. Erratum in: Hepatology. 2010 May;51(5):1868.

PMID:
19824078
41.

Noninvasive assessment of fibrosis and steatosis in NASH and ASH.

Angulo P.

Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):940-8. doi: 10.1016/j.gcb.2009.08.001. Epub 2009 Oct 1.

42.

Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.

Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE.

Hepatology. 2009 Oct;50(4):1113-20. doi: 10.1002/hep.23133.

43.

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years.

Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P.

Gut. 2009 Nov;58(11):1538-44. doi: 10.1136/gut.2008.171280. Epub 2009 Jul 21.

44.

Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Charatcharoenwitthaya P, Talwalkar JA, Angulo P, Gossard AA, Keach JC, Petz JL, Jorgensen RA, Lindor KD.

Dig Dis Sci. 2010 Feb;55(2):476-83. doi: 10.1007/s10620-009-0744-1. Epub 2009 Mar 3.

PMID:
19255851
45.

Cholangiocarcinoma in pregnancy: a case report.

Marasinghe JP, Karunananda SA, Angulo P.

J Obstet Gynaecol Res. 2008 Aug;34(4 Pt 2):635-7. doi: 10.1111/j.1447-0756.2008.00810.x.

PMID:
18840169
46.

Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB.

Am J Gastroenterol. 2008 Sep;103(9):2263-71. doi: 10.1111/j.1572-0241.2008.02034.x. Epub 2008 Aug 5.

47.

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P.

Hepatology. 2008 Jul;48(1):119-28. doi: 10.1002/hep.22336.

PMID:
18537181
48.

The natural history of small-duct primary sclerosing cholangitis.

Björnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P.

Gastroenterology. 2008 Apr;134(4):975-80. doi: 10.1053/j.gastro.2008.01.042. Epub 2008 Jan 17.

PMID:
18395078
49.

Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.

Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, Lindor K.

Hepatology. 2008 Feb;47(2):484-92. doi: 10.1002/hep.22063.

50.

Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.

Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD.

Hepatology. 2008 Jan;47(1):133-42.

PMID:
17992695

Supplemental Content

Loading ...
Support Center